WallStreetZenWallStreetZen

NASDAQ: XLO
Xilio Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their XLO stock forecasts and price targets.

Forecast return on equity

Is XLO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is XLO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

XLO revenue forecast

What is XLO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$30.0M
Avg 2 year Forecast
$75.0M
Avg 3 year Forecast
$12.5M

XLO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XLO$1.05N/AN/A
BCLI$0.53N/AN/A
OKYO$1.40$7.00+400.00%Buy
ICU$0.49N/AN/A
BCTX$2.32$18.00+675.86%Buy

Xilio Therapeutics Stock Forecast FAQ

What is XLO's revenue growth forecast for 2024-2026?

(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Xilio Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast XLO's revenue for 2024 to be $1,034,204,580, with the lowest XLO revenue forecast at $1,034,204,580, and the highest XLO revenue forecast at $1,034,204,580. On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $2,585,511,450, with the lowest XLO revenue forecast at $2,585,511,450, and the highest XLO revenue forecast at $2,585,511,450.

In 2026, XLO is forecast to generate $430,918,575 in revenue, with the lowest revenue forecast at $430,918,575 and the highest revenue forecast at $430,918,575.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.

What is XLO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: XLO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is XLO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: XLO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.